Nine public health organizations submitted a letter to US House and Senate committees citing concerns about Section 11 of the FDA and NIH Workforce Authorities Modernization Act.
Caroline Hroncich
Advertisement
Caroline Hroncich was associate editor for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International from 2015 to 2017.
Articles by Caroline Hroncich
Keytruda was shown to be superior to chemotherapy in the treatment of patients with non-small cell lung cancer.
A study published in BMJ indicates that rheumatic patients with anti-infliximab antibodies may have a similar cross reaction to infliximab biosimilars.
The agency reiterated its earlier decision to require suffixes in biosimilar naming, but was unclear on suffix meaning.
Genentech received accelerated approval for its immunotherapy atezolizumab for the treatment of bladder cancer.
Advertisement
Latest Updated Articles
- FDA Approves Atezolizumab
Published: May 19th 2016 | Updated:
- FDA Reiterates Decision to Require Suffixes in Biosimilar Naming
Published: June 6th 2016 | Updated:
- Study: Patients Who Have Reactive Responses to Infliximab Should Not Switch to Biosimilar Versions
Published: June 15th 2016 | Updated:
- Keytruda Proves Superior to Chemotherapy in Phase III Trials
Published: June 16th 2016 | Updated:
- Public Health Organizations Pen Letter to House and Senate Committees
Published: August 17th 2016 | Updated:
Advertisement
Advertisement
